drugset

drugset / Trial / NCT04887948

Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2

NCT04887948 ↗

Phase 3 Completed 570 enrolled Pfizer

RandomizedParallel-groupTriple-blindPrevention

Summary

Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone

Timeline

Start: 2021-05-20
Primary completion: 2021-12-08
Completion: 2021-12-08

Publications

Fitz-Patrick D, Young M, Yacisin K, McElwee K, Belanger T, Belanger K, Peng Y, Lee DY, Gruber WC, Scott DA, Watson W. Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults >/=65 years old. Vaccine. 2023 Jun 23;41(28):4190-4198. doi: 10.1016/j.vaccine.2023.05.002. Epub 2023 May 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	20vPnC	Vaccine	—	Other
Subject	BNT162b2	Messenger RNA (mRNA)	—	Other

Indications